Press Releases

Investors

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arrowhead Pharmaceuticals Reports Fiscal 2018 Year End Results
Conference Call and Webcast Today at 4:30 p.m. EST PASADENA, Calif. --(BUSINESS WIRE)--Dec. 11, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2018 fourth quarter and year ended September 30, 2018 .
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Webcast 2018 Fiscal Year End Results
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 27, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on December 11, 2018 , at 4:30 p.m. EST to discuss its financial results for the fiscal year ended September 30, 2018 .
View HTML
Toggle Summary Arrowhead Pharmaceuticals Presents Late-Breaking Preliminary Clinical Data on ARO-HBV at Liver Meeting® 2018
- Mean HBsAg reduction of -1.9 Log10 (-98.7%) with a range of -1.3 Log10 (-95.0%) to -3.8 Log10 (-99.98%) - ARO-HBV appears to be well-tolerated at monthly doses up to 400 mg PASADENA, Calif. --(BUSINESS WIRE)--Nov. 9, 2018-- Arrowhead Pharmaceuticals Inc.
View HTML
Toggle Summary Arrowhead Pharmaceuticals Presents Late-Breaking Clinical Data on ARO-AAT at Liver Meeting® 2018
Three monthly doses of 300 mg ARO-AAT led to reductions in serum alpha-1 antitrypsin to below the level of quantitation in 100% of subjects Reductions were sustained for greater than 14 weeks indicating that quarterly or less frequent dosing appears feasible Single and multiple doses of ARO-AAT
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Present at Upcoming November 2018 Conferences
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 1, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to present at the following upcoming events: BIT’s 16th Annual Congress of International Drug Discovery Science and Technology – Jinan, China , November 6-8, 2018
View HTML
Toggle Summary Arrowhead Pharmaceuticals Announces Closing of Agreements with Janssen
PASADENA, Calif. --(BUSINESS WIRE)--Oct. 31, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the license agreement and research collaboration and option agreement between Arrowhead and Janssen Pharmaceuticals, Inc. , part of the Janssen Pharmaceutical Companies of Johnson
View HTML
Toggle Summary Arrowhead Pharmaceuticals Hosts R&D Day on Pipeline of RNAi Therapeutics
PASADENA, Calif. --(BUSINESS WIRE)--Oct. 16, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) is hosting a Research & Development (R&D) Day today in New York to discuss its emerging pipeline of RNAi therapeutics that leverage the Company’s proprietary Targeted RNAi Molecule (TRiM™) platform.
View HTML
Toggle Summary Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-ANG3
— Arrowhead to host R&D Day October 16, 2018 to discuss ARO-ANG3 and its emerging pipeline of RNAi therapeutics PASADENA, Calif. --(BUSINESS WIRE)--Oct. 15, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for approval to begin a Phase 1 clinical
View HTML
Toggle Summary Arrowhead to Present Late-Breaking Clinical Data on ARO-AAT and ARO-HBV at AASLD Liver Meeting® 2018
PASADENA, Calif. --(BUSINESS WIRE)--Oct. 11, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) will make two late-breaking poster presentations at The Liver Meeting® 2018, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) being held on November 9-13, 2018 , in
View HTML
Toggle Summary Arrowhead Enters $3.7 Billion License and Collaboration Agreements with Janssen
- Upon closing, Arrowhead to receive $250 million , consisting of $175 million upfront payment from Janssen and $75 million equity investment from Johnson & Johnson Innovation – JJDC, Inc. - Arrowhead eligible to receive additional $3.5 billion in potential milestone payments, and potential further
View HTML